Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NLX P101

Drug Profile

NLX P101

Alternative Names: AAV-GAD; GAD gene therapy; NLX-P-101; STN AAV-GAD gene therapy

Latest Information Update: 16 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cornell University; Neurologix
  • Developer Neurologix
  • Class Antiparkinsonians; Gene therapies
  • Mechanism of Action GABA modulators; Glutamate modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 09 Oct 2018 Vector Neurosciences has been acquired and merged into MeiraGTx
  • 09 Oct 2018 Updated adverse events data from a phase II trial in Parkinson's disease released by Vector Neurosciences
  • 22 Apr 2013 Diamyd Medical is now called Mertiva
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top